Ptc Therapeutics (PTCT) Net Cash Flow (2012 - 2026)

Ptc Therapeutics' Net Cash Flow history runs 15 years deep, the most recent figure standing at -$146.4 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 121.06% year-over-year to -$146.4 million in Q1 2026; TTM through Mar 2026 was -$661.2 million, a 171.01% decrease from a year earlier, with the FY2025 full-year figure at $180.3 million, down 6.27% from the prior year.
• Net Cash Flow retreated to -$146.4 million in Q1 2026 per PTCT's latest filing, from $302.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $695.2 million in Q1 2025 and bottomed at -$476.4 million in Q2 2025.
• The 5-year median for Net Cash Flow is -$40.8 million (2023), against an average of $37.6 million.
• Across the five-year window, Net Cash Flow jumped 4371.86% in 2022 and sank 536.62% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $169.4 million in 2022, then soared by 151.35% to $425.8 million in 2023, then sank by 37.95% to $264.2 million in 2024, then climbed by 14.41% to $302.2 million in 2025, then slumped by 148.43% to -$146.4 million in 2026.
• Per Business Quant, the three latest PTCT Net Cash Flow figures stand at -$146.4 million (Q1 2026), $302.2 million (Q4 2025), and -$340.7 million (Q3 2025).